AR and prostate cancer: Moreover, in a study using human LNCaP human prostate cancer xenografts in mice, it was reported that the growth inhibition of tumors was accompanied by the downregulation of the androgen receptor (AR) and a decrease in prostate-specific antigen (PSA) levels [121].